Patents by Inventor Haiqun Liu

Haiqun Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-SERUM ALBUMIN BINDING VARIANTS
    Publication number: 20110305696
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Application
    Filed: February 17, 2010
    Publication date: December 15, 2011
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Christopher Plummer, Oliver Schon
  • ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
    Publication number: 20110301335
    Abstract: The invention relates to anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.
    Type: Application
    Filed: February 17, 2010
    Publication date: December 8, 2011
    Inventors: Stephen Duffield, Carolyn Enever, Haiqun Liu, Oliver Schon, Armin Sepp, Adriaan Allart Stoop
  • ANTI-SERUM ALBUMIN BINDING VARIANTS
    Publication number: 20110300158
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Application
    Filed: February 17, 2010
    Publication date: December 8, 2011
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
  • COMPOSITIONS MONOVALENT FOR CD40L BINDING AND METHODS OF USE
    Publication number: 20110172400
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD4OL. Antibody polypeptides that are monovalent for binding of CD4OL can inhibit CD4OL activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC4OL. in one aspect, a monovalent anti-CD4OL antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC4OL, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD4OL antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD4OL interactions in an individual and methods of treating diseases or disorders involving CD40/DC4OL interactions, the methods involving administering a monovalent anti-CD4OL antibody polypeptide to the individual.
    Type: Application
    Filed: November 8, 2010
    Publication date: July 14, 2011
    Applicant: Domantis Limited
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
  • Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptides
    Patent number: 7927596
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: April 19, 2011
    Assignee: Domantis Limited
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
  • CD40L-specific monovalent polypeptides
    Patent number: 7829096
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: November 9, 2010
    Assignee: Domantis Ltd.
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
  • Compositions monovalent for CD40L binding and methods of use
    Publication number: 20100092482
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
    Type: Application
    Filed: May 1, 2009
    Publication date: April 15, 2010
    Applicant: Domantis Limited
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
  • Compositions monovalent for CD40L binding and methods of use
    Publication number: 20100092483
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
    Type: Application
    Filed: May 1, 2009
    Publication date: April 15, 2010
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
  • LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR
    Publication number: 20100056439
    Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.
    Type: Application
    Filed: December 5, 2006
    Publication date: March 4, 2010
    Applicant: DOMANTIS LIMITED
    Inventors: Roland Beckmann, Rudolf M T De Wildt, Steve Holmes, Olga Ignatovich, Laurent S Jespers, Haiqun Liu, Malgorzata Pupecka, Armin Sepp, Michael Steward
  • Compositions monovalent for CD40L binding and methods of use
    Publication number: 20090297524
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
    Type: Application
    Filed: September 16, 2005
    Publication date: December 3, 2009
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
  • Monovalent anti-CD40L antibody polypeptides and compositions thereof
    Patent number: 7563443
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: July 21, 2009
    Assignee: Domantis Limited
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
  • Antibodies Against Candida Antigens
    Publication number: 20080193450
    Abstract: This invention relates to domain antibodies. In particular, it relates to domain antibodies (dAbs) that recognize virulence traits of Candida spp. and confer passive protection against candidiasis.
    Type: Application
    Filed: March 10, 2006
    Publication date: August 14, 2008
    Inventors: Antonio Cassone, Flavia De Bernardis, Steven Grant, Haiqun Liu
  • Compositions monovalent for CD40L binding and methods of use
    Publication number: 20060062784
    Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
    Type: Application
    Filed: April 8, 2005
    Publication date: March 23, 2006
    Inventors: Steven Grant, Haiqun Liu, Kevin Moulder